Derma Sciences Inc ( NASDAQ: DSCI ) reports positive follow up results in Phase II trials of DSC127.

Derma Sciences Inc ( NASDAQ: DSCI ) reports positive follow up results of its Phase II trials of DSC127. Stock jumped more than 18 % in the morning trade. Traders might initiate buy position for intraday gains, but one might not see a huge upside in the stock ( like 50-60 % ).

Below is the detailed news:

Derma Sciences Inc
Derma Sciences, Inc. announced that in the follow-up portion of its Phase 2 clinical trial in patients with diabetic foot ulcers, the percentage of patients treated with the therapeutic (0.03%) dose of DSC127 with complete healing at 24 weeks following trial enrollment was 73% in the intent-to-treat (ITT) population and 85% in the per-protocol population (PP), a difference of 27 and 33 percentage points, respectively, compared with patients treated with placebo/standard of care (placebo). DSC127 is a patented, topically applied angiotensin analog that targets receptors that are up-regulated upon injury to tissue. Healing was defined as 100% epithelialized with no drainage. The Company previously announced that the 0.03% dose of DSC127 exceeded the trial’s goal of an improvement of 15 percentage points in complete healing of wounds at 12 weeks for both the ITT (21 percentage point increase) and PP (27 percentage point increase) populations, compared with placebo.
With today’s announcement, the improvement at 24 weeks between patients treated with DSC127 0.03% and patients treated with placebo is even more pronounced. There were no drug-related adverse safety events during the entire 24-week study period. The double-blind, placebo-controlled, multi-center Phase 2 clinical trial randomized 80 patients to receive one of two dose strengths of DSC127 (0.03% or 0.01%) or vehicle placebo control.

( Source: Reuters )
Tags: , , ,

About author

Make it happen !!


Leave a Reply